



SEPAR/ALAT Voice

## SEPAR Position Paper on the Use of High Flow Nasal Cannula Therapy in the Home Setting



Raúl Moreno-Zabaleta<sup>a,\*</sup>, Manel Luján Torne<sup>b,c</sup>, Javier Sayas Catalán<sup>d</sup>, Pedro García Torres<sup>e</sup>, Daniel López Padilla<sup>f</sup>, Mar Mosteiro Añón<sup>g</sup>, Sergi Martí Beltrán<sup>h,i</sup>, Ascensión Hernando Sanz<sup>d</sup>, Mónica González Martínez<sup>j</sup>, Olga Mediano<sup>k,l,m,n</sup>

<sup>a</sup> Servicio de Neumología, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Facultad de Medicina, Salud y Deportes, Departamento de Medicina, FIIB-HUIS-HUHEN, San Sebastián de los Reyes, Spain

<sup>b</sup> Servei de Pneumologia, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red, Madrid, Spain

<sup>d</sup> Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>e</sup> Servicio de Neumología, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain

<sup>f</sup> Servicio de Neumología, Hospital Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain

<sup>g</sup> Servicio de Neumología, Complejo Universitario de Vigo, Vigo, Spain

<sup>h</sup> Servicio de Neumología, Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>i</sup> Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain

<sup>j</sup> Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain

<sup>k</sup> Unidad de Sueño, Servicio de Neumología, Hospital Universitario de Guadalajara, Guadalajara, Spain

<sup>l</sup> Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

<sup>m</sup> Instituto de Investigación Sanitaria Castilla la Mancha (IDISCAM), Toledo, Spain

<sup>n</sup> Departamento de Medicina, Universidad de Alcalá, Madrid, Spain

### ARTICLE INFO

#### Article history:

Received 14 April 2025

Accepted 18 April 2025

Available online 26 April 2025

#### Keywords:

High flow nasal cannula therapy

High flow oxygen

Chronic use of high flow nasal cannula therapy

Domiciliary use of nasal cannula therapy

### ABSTRACT

The purpose of this document is to establish SEPAR's official position on the use of high-flow nasal cannula (HFNC) therapy in the home management of patients with chronic respiratory diseases. This position statement is deemed necessary considering current evidence regarding HFNC use in chronic respiratory conditions, with the objective of standardizing its application. This consensus was developed by a panel of experts comprising specialists with established expertise in chronic respiratory failure and high-flow nasal cannula therapy. The panel of experts established recommendations in COPD, bronchiectasis, interstitial lung diseases, palliative care, rehabilitation, and chronic treatment settings.

© 2025 SEPAR. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

### Introduction

The purpose of this document is to establish SEPAR's official position on the use of high-flow nasal cannula (HFNC) therapy in the home management of patients with chronic respiratory diseases. This position statement is deemed necessary considering current evidence regarding HFNC use in chronic respiratory conditions, with the objective of standardizing its application.

While the role of HFNC in acute respiratory failure is well-established,<sup>1</sup> the clinical evidence supporting its prolonged use at home remains limited. This position statement is founded on a comprehensive review of existing scientific literature concerning

the efficacy and safety of HFNC therapy in the home environment, alongside a consensus among clinical experts. It also provides recommendations to assist healthcare professionals in utilizing this therapy for patients with chronic respiratory diseases such as COPD, bronchiectasis, interstitial lung disease (ILD), and in palliative care contexts.

Chronic respiratory diseases, including Chronic Obstructive Pulmonary Disease (COPD), are among the leading causes of morbidity and mortality worldwide.<sup>2,3</sup> Together with bronchiectasis<sup>4,5</sup> and interstitial lung disease,<sup>6</sup> they constitute a significant burden in terms of morbidity and mortality among respiratory patients. In advanced stages, with chronic respiratory failure, management has traditionally relied on conventional oxygen therapy (COT) and more recently on home non-invasive ventilation (NIV). However, both modalities have notable limitations regarding outcomes and

\* Corresponding author.

E-mail address: [morenozabaleta@gmail.com](mailto:morenozabaleta@gmail.com) (R. Moreno-Zabaleta).

patient adherence,<sup>7</sup> prompting the exploration of more effective alternatives.

In this context, HFNC has emerged as a promising intervention for the home management of patients with chronic respiratory diseases, due to its capacity to improve ventilation, enhance mucociliary clearance, and reduce the work of breathing.<sup>8,9</sup> Additionally, there is accumulating evidence supporting its role in reducing exacerbations<sup>10,11</sup> and hospitalizations,<sup>12</sup> as well as enhancing patient comfort and quality of life.<sup>10</sup> Despite these promising findings, uncertainties persist regarding the optimal integration of HFNC into the management of chronic respiratory diseases. Key considerations include patient selection, appropriate indications, combinations with other therapies, and therapeutic escalation, as HFNC is not a universal treatment for all patients with chronic respiratory failure.<sup>13</sup> Results from ongoing controlled trials and real-world studies<sup>14</sup> are crucial to further elucidate the effectiveness of HFNC in this patient population.

## Methodology

This consensus was developed by a panel of experts comprising specialists with established expertise in chronic respiratory failure and high-flow nasal cannula therapy. All the methodology of work is explained in the [online supplement](#). Final recommendations are in [Tables 1 and 2](#).

## Current Evidence and Review of Physiological Effects of HFNC

HFNC is a non-invasive respiratory support method that delivers heated and humidified oxygen-enriched air at flow rates exceeding 15 L/min.<sup>1</sup>

**Table 1**

Chronic use of HFNC panel recommendations.

Chronic use of HFNC	Recommendations
Stable severe COPD patients with excessive secretions	Chronic use HFNC suggested
Stable COPD patients with hipercapnia who do not tolerate NIV	Chronic use HFNC suggested
Bronchiectasis patients to reduce exacerbation	Chronic use HFNC suggested
Bronchiectasis patients to improve mucociliary clearance	Chronic use HFNC suggested
ILD patients to improve exercise tolerance	Chronic use HFNC suggested
ILD patients to improve oxigenation without a reliable oxygen source	Not recommended
Palliative care patients to relief symptoms	Chronic use HFNC suggested
Palliative care patients for a treatment trial	Chronic use HFNC recommended
Palliative care patients with individualized decision and agreement	Chronic use HFNC recommended
During rehabilitation in COPD patients to reduce dyspnoea	Chronic use HFNC suggested
During rehabilitation in ILD patients	Not recommended

Red: not recommended; Orange: suggested; Green: recommended.

## Physiological Effects

The physiological effects of HFNC are well-documented, and in the context of home and chronic care, they include:

- **Improved mucociliary clearance<sup>15</sup>:** It is well known that the respiratory epithelium is sensitive to pressure and humidity to maximize its function. Low humidity, as generated by conventional oxygen flows, can alter the viscosity of respiratory secretions and impair mucociliary clearance and ciliary function. Additionally, low inhaled air temperatures can induce bronchoconstriction in patients with COPD, bronchiectasis, or asthma.
- **Dead space washout<sup>16</sup>:** It may be less relevant in the home care setting compared to acute care because patients in a home setting typically have a lower respiratory rate, which improves exhalation time and reduces dead space re-inhalation. This effect is closely related to CO<sub>2</sub> clearance, although the lower flow rates used in home care may limit its benefit.
- **Stable FiO<sub>2</sub>:** In situations requiring high flows, HFNC can provide stable FiO<sub>2</sub>. However, this is less relevant in home care since the high FiO<sub>2</sub> levels needed in acute care are generally unnecessary.
- **Counterbalancing intrinsic PEEP:** In acute care, high flow rates are required to achieve oropharyngeal positive end-expiratory pressure (PEEP) to counterbalance intrinsic PEEP. In home care, lower flow rates may suffice as air trapping is typically less severe than during an exacerbation.<sup>17</sup> Care should be taken to avoid excessive flow rates that might lead to undesirably high alveolar pressures in stable COPD patients.<sup>18,19</sup> Finally, the PEEP-related benefits of HFNC may be diminished when used with a tracheostomy, as the PEEP effect is largely generated at the nasopharyngeal level due to the interaction of patient expiratory flow and continuous high flow from the device.<sup>20</sup>
- **Reducing work of breathing:** HFNC reduces the work of breathing by decreasing respiratory rate and accessory muscle use or by directly lowering the work of breathing as measured by transpulmonary pressure. This effect is evident in acute care settings.<sup>9,21–23</sup> Preliminary research suggests a reduction in neural respiratory drive in home care settings with promising results.<sup>21</sup>
- **Improvement in pulmonary mechanics<sup>21</sup>:** HFNC can enhance pulmonary mechanics, including improvements in end-expiratory lung volume, compliance, and air distribution homogeneity, which are well-established in acute care. In home care, HFNC has shown improvements in pulmonary function, such as increased FEV1 and FVC in patients with bronchiectasis.<sup>24</sup> In stable COPD patients and healthy volunteers, HFNC reduces respiratory rate and increases tidal volume, promoting a deeper and slower breathing pattern compared to COT.<sup>22</sup> This can be shown by reducing ventilation inhomogeneity, increasing end-expiratory

**Table 2**

Settings of chronic use of HFNC recommendations.

Settings of chronic use of HFNC	Recommendations
Flows between 20-30 L/min	Chronic use HFNC recommended
Starting with temperature of 31°C and increase to 37°C if tolerated	Chronic use HFNC recommended
Supplemental O2 Flow adjusted to achieve the desired SpO2	Chronic use HFNC recommended
Use at least during nocturnal time	Chronic use HFNC recommended

Red: not recommended; Orange: suggested; Green: recommended.

lung volumes, improving lung compliance and improving oxygenation and hypercapnia.<sup>23</sup>

### Treatment Objectives

The primary goals of HFNC in the home setting are to reduce the work of breathing and improve patient comfort and quality of life. For patients with chronic respiratory diseases, HFNC aims to manage symptoms, prevent exacerbations, and enhance overall respiratory function. By maintaining optimal humidity levels, HFNC supports mucociliary function and reduces the risk of respiratory infections.

### Physiological Recommendations

Based on current evidence, HFNC is a promising option for home use in patients with chronic respiratory diseases. Key physiological effects include:

- Improving lung mechanics, leading to a deeper and slower breathing pattern.
- Decreasing neural respiratory drive, allowing muscular rest.
- Enhancing gas exchange and reducing hypercapnia.
- Improving mucus clearance.
- Increasing tolerance compared to conventional oxygen therapy.

### Chronic Use of HFNC in Stable COPD

As previously discussed, from a physiological perspective, HFNC can be beneficial for patients with stable COPD when used long-term at home.<sup>15–17,21,25</sup> Based on the physiological effects, studies evaluating the impact of HFNC on stable COPD have focused on three primary outcomes: the number of exacerbations and hospitalizations, baseline PaCO<sub>2</sub> levels, and quality of life, physical activity, dyspnea, and lung function.<sup>17</sup>

#### Clinical Evidence for Chronic Use of HFNC in Stable COPD

- Effects of HFNC on reducing exacerbations: Three randomized controlled trials have evaluated the effect of HFNC on COPD exacerbations compared to conventional oxygen therapy. A study published in 2010<sup>26</sup> randomized 108 patients with COPD or bronchiectasis who had more than two exacerbations in the previous year to receive either high-flow therapy or conventional oxygen for one year. The time to the first exacerbation was significantly longer in the group treated with high-flow therapy. The number of exacerbations over one year was also lower in the HFNC group, although this did not reach statistical significance. Despite the results, the average usage of HFNC in this study did not exceed 2 h per day. Nagata et al.<sup>27</sup> also evaluated the time to the first exacerbation in 104 patients with COPD and chronic hypercapnia, compared conventional oxygen therapy with at least 4 daily hours of HFNC at approximately 30 L/min. Patients treated with conventional oxygen alone experienced more than twice the number of exacerbations compared to those treated with HFNC. Two additional studies showed similar results. A 2018 study from Denmark,<sup>28</sup> which included 200 patients with COPD and chronic respiratory failure, treated with nocturnal HFNC and daytime conventional oxygen or only conventional oxygen for one year, also demonstrated a reduction in the number of exacerbations in the HFNC group (3.12 exacerbations per year in the high-flow + oxygen group vs. 4.95 in the oxygen-alone group). A post hoc analysis of this study, published in 2019,<sup>29</sup> indicated that the reduction in exacerbations was particularly significant in patients with more than two exacerbations in the previous year,

suggesting that those with frequent exacerbations may derive the most benefit from this therapy.

- Effects of HFNC on reducing hospitalizations: Evidence regarding the impact of HFNC on hospitalizations is more limited. The Danish study by Storgaard et al.<sup>28</sup> evaluated hospital admissions as a secondary endpoint, showing a reduction in hospital admissions in the HFNC group, although this did not reach statistical significance. A post hoc analysis of the study, published in 2020, revealed that the group treated with HFNC experienced a statistically significant reduction in hospital admissions in the year following treatment initiation.<sup>30</sup> Recently a prospective multicenter study including 27 COPD exacerbators GOLD III and IV patients treated a year with home HFNC have showed decreased in exacerbations rate, hospital admissions, and in-hospital days.<sup>31</sup>
- Effects of HFNC on baseline PaCO<sub>2</sub>: Several studies have examined the potential of HFNC to reduce baseline PaCO<sub>2</sub> in hypercapnic stable COPD patients. Studies comparing baseline PaCO<sub>2</sub> in hypercapnic COPD patients treated with HFNC versus COT generally show improvements in PaCO<sub>2</sub> associated with HFNC. One study randomized 74 patients with chronic hypercapnic COPD to conventional oxygen therapy or HFNC and assessed PaCO<sub>2</sub> at 6 months and after a year.<sup>30</sup> Baseline PaCO<sub>2</sub> was lower in the HFNC group at both 6 months and one year. In each assessment, patients were connected to HFNC for 30 min, and PaCO<sub>2</sub> was measured before and after the session, showing decreases in PaCO<sub>2</sub> in that time. The Nagata et al.<sup>32</sup> study, which had a secondary objective of analyzing both baseline and nocturnal PaCO<sub>2</sub>, reported a reduction of 4.1 mmHg in baseline PaCO<sub>2</sub> and 5.1 mmHg in nocturnal PaCO<sub>2</sub>. In 2019, Bräunlich et al.<sup>33</sup> published a randomized crossover study involving 94 patients with COPD and a mean baseline PaCO<sub>2</sub> of 56 mmHg. Patients were consecutively treated with HFNC combined with daytime conventional oxygen, and nocturnal NIV combined with daytime COT. PaCO<sub>2</sub> levels decreased by 7.1% with NIV and by 4.7% with HFNC, both statistically significant reductions. The authors concluded that HFNC could be a viable alternative for patients who do not tolerate NIV.
- Effects of HFNC on quality of life, dyspnea, exercise capacity, and lung function: Most studies evaluating HFNC in stable COPD include secondary objectives analyzing its impact on quality of life, dyspnea, exercise capacity, and lung function.<sup>28,29,32,33</sup> Overall, improvements in quality of life are consistently observed. These outcomes will be further reviewed in the section on chronic use of HFNC in rehabilitation.

#### Recommendations for Chronic Use of HFNC in Stable COPD

- The group suggests the use of HFNC in stable severe COPD patients with excessive secretions (chronic bronchitis) to reduce exacerbations, improve control of chronic bronchial infection, and enhance quality of life. The evidence regarding its impact on reducing hospital admissions is less conclusive.
- The group suggests the use of HFNC in stable COPD patients with hypercapnia who do not tolerate NIV, with the objective of improving baseline PaCO<sub>2</sub>.

### Chronic Use of HFNC in Bronchiectasis

In bronchiectasis, chronic inflammation and persistent mucus retention drive recurrent exacerbations and contribute to airway damage.<sup>34–36</sup> The physiological effects of HFNC can be beneficial for patients with bronchiectasis when used long-term at home.

HFNC is useful for interrupting the cycle of recurrent infections and reducing airway obstruction caused by mucus plugs.<sup>11,37</sup>

Furthermore, HFNC reduces the work of breathing and improves gas exchange, which is particularly advantageous for patients with severe disease.<sup>26,37</sup> Consequently, the introduction of HFNC has shown promise, especially in reducing exacerbations and improving quality of life.

#### *Clinical Evidence for Chronic Use of HFNC in Bronchiectasis*

Several studies have demonstrated the benefits of long-term HFNC therapy in bronchiectasis. Simioli et al. in 2023<sup>37</sup> showed that long-term HFNC significantly reduced the frequency of acute exacerbations and hospitalizations in patients with both primary and secondary bronchiectasis. In a cohort of 78 patients, the mean number of exacerbations decreased from 2.81 to 0.45 over two years, with significant improvements in dyspnea scores, although no significant changes were observed in lung function parameters such as forced expiratory volume in one second (FEV<sub>1</sub>) and forced vital capacity (FVC). Similarly, a study by Crimi et al.<sup>24</sup> demonstrated that HFNC use in bronchiectasis patients resulted in a significant reduction in exacerbation rates and hospitalizations, along with improvements in lung function markers such as FEV<sub>1</sub> and FVC. A post hoc analysis by Good et al.<sup>38</sup> further emphasized the efficacy of HFNC in reducing exacerbation rates in patients with stable bronchiectasis, showing a 31.3% reduction in exacerbations compared to usual care and significant improvements in quality of life as measured by the St. George's Respiratory Questionnaire. Additionally, Rea et al. in 2010<sup>26</sup> confirmed that HFNC therapy prolonged the time to first exacerbation and reduced the number of exacerbation days in patients with both chronic COPD and bronchiectasis, with more patients remaining exacerbation-free, indicating its utility in managing these chronic respiratory conditions. Recently, a total of 86 non-cystic fibrosis bronchiectasis patients with at least one severe exacerbation in the previous year were enrolled in one-year prospective study. The results showed that long-term HFNC reduces the annual exacerbation rate.<sup>39</sup>

Adherence to long-term HFNC is generally high, with most studies reporting usage rates between 5 and 8 h per day. HFNC is well tolerated, with minimal side effects reported. Safety data from these studies suggest that the therapy is associated with few adverse events, making it a viable option for home use.<sup>11,37,40</sup>

#### *Recommendations for Chronic Use of HFNC in Bronchiectasis*

- The group suggests the use of HFNC for patients with bronchiectasis to reduce the frequency of exacerbations, improve quality of life, and potentially enhance lung function.
- The group suggests the use of HFNC to improve mucociliary clearance and reduce the work of breathing. It makes HFNC particularly valuable in managing the chronic symptoms of bronchiectasis.

#### **Chronic Use of HFNC in Interstitial Lung Diseases**

Interstitial lung diseases (ILD) are characterized by a variable and often progressive course, with symptoms such as exertional dyspnea.<sup>41</sup> The disease course may be complicated by acute respiratory failure and, in advanced stages, by chronic respiratory failure. In the acute setting, HFNC has been shown to be superior to COT and not inferior NIV in treating severe hypoxemic acute respiratory failure, offering better comfort and patient perception.<sup>42,43</sup> However, limited data are available on the use of HFNC in chronic and home settings, particularly in ILD.<sup>11,44</sup>

#### *Clinical Evidence for Chronic Use of HFNC in Interstitial Lung Diseases*

Weinreich et al. conducted a pilot crossover study of domiciliary HFNC in 9 ILD patients already receiving either ambulatory oxygen therapy or long-term oxygen therapy over a 6-week period.<sup>45</sup> Patients were instructed to use the HFNC for 8 h a day, preferably during nighttime, at a flow rate of 30 L/min, with oxygen flow at their previously prescribed level (FiO<sub>2</sub> on HFNC at 0.26). Patients used HFNC for an average of 6.5 h per day, which was associated with improvements in the 6-minute walk test (6MWT) distance (441 vs. 393 m) and breathlessness (mMRC score). No significant effects were observed on lung function, blood gas analyses, or quality of life.

HFNC has also been shown to improve exercise tolerance better than COT in ILD patients with exertional desaturation, as evidenced by increased endurance time during a cardiopulmonary exercise test.<sup>46–49</sup> An inverse correlation was found between mean SpO<sub>2</sub> values during the baseline room air 6MWT and improvements in endurance time with HFNC, suggesting that HFNC might be particularly beneficial for patients with greater exertional hypoxemia.<sup>46</sup> These findings support the potential use of HFNC during pulmonary rehabilitation, although further studies are needed to explore its application in home settings.<sup>50</sup>

HFNC has also been used in end-of-life and palliative care settings for ILD patients, where management often focuses on symptom relief and improving quality of life, facilitating discharge from acute care facilities.<sup>51</sup>

However, a recent study published in late 2024 showed that adherence to home HFNC in patients with ILD was low, possibly due to the limited impact of this treatment on symptom relief.<sup>52</sup> Although the expected benefits of HFNC in ILD patients include improved exercise capacity and reduced breathlessness, given the importance of correcting desaturation, a significant challenge remains ensuring a home oxygen source, such as concentrators or liquid oxygen, capable of delivering the high FiO<sub>2</sub> required during exercise and in end-stage lung disease.

#### *Recommendations for Chronic Use of HFNC in Interstitial Lung Diseases*

- The group suggests the use of HFNC for ILD patients to improve exercise tolerance, though the current evidence is of low grade.
- The group doesn't recommend using HFNC without a reliable oxygen source, capable of delivering an adequate flow rate for patients with high FiO<sub>2</sub> requirements.

#### **Chronic Use of HFNC in Palliative Care**

The effects of HFNC at home may meet the criteria to be considered a suitable end-of-life treatment<sup>53–56</sup> due to its physiological benefits<sup>53,54,56–58</sup> and user-friendly characteristics.<sup>12,51,59,60</sup> However, most evidence supporting its use comes from outside the palliative care context.

#### *Clinical Evidence for Chronic Use of HFNC in Palliative Care*

Studies focusing on the use of HFNC at home during the end-of-life stage are limited.<sup>54,61</sup> Dolidon et al.<sup>51</sup> conducted a retrospective study involving 71 patients with terminal respiratory failure from various aetiologies, demonstrating that HFNC therapy enabled patients to be discharged and remain at home with acceptable survival rates and reasonable costs. In elderly populations<sup>60</sup> or those with a Do Not Intubate order,<sup>62–65</sup> HFNC has shown positive effects,



though key aspects remain unclear. Most studies compare HFNC with conventional treatments:

- HFNC vs. COT: A hospital-based study<sup>66</sup> demonstrated the superiority of HFNC in reducing dyspnea within the first hour in patients with a Do Not Intubate order and hypoxemic respiratory failure.
- HFNC vs. NIV: Hospital studies suggest similar benefits with better tolerance for HFNC.<sup>67</sup> Peters et al.,<sup>63</sup> in a retrospective observational study, supported the use of HFNC over NIV for adequate oxygenation in patients with terminal respiratory disease and hypoxemic respiratory failure under a Do Not Intubate order. These findings may be extrapolated to home settings. Other studies found HFNC at the same level of NIV benefits, with better tolerance.<sup>51,68,69</sup> However, only the French study<sup>47</sup> offers a domiciliary perspective. In cases of ILD and oncological diseases with respiratory involvement, HFNC significantly improved oxygenation and dyspnea and was well tolerated.<sup>63,65–67,70,71</sup>

The goals of palliative HFNC include optimizing opioid use for symptom control, maintaining oxygenation levels at home, reducing the need for prolonged hospitalization, and enabling oral communication and feeding. HFNC provides a less traumatic interface, easing the burden on caregivers.<sup>72</sup> Huang et al.<sup>64</sup> recommend a flow rate of 20 L/min over seven to eight hours, preferably at night.

#### *Recommendations for Chronic Use of HFNC in Palliative Care*

- The group suggests the use of HFNC to a symptomatic treatment strategy for end-of-life patients with respiratory disease, with the potential for symptom relief, improved quality of life, and avoidance of unwanted hospitalization.
- The group recommends using HFNC for a treatment trial to evaluate symptom relief and ensure the absence of adverse effects or harm.
- The group recommends using HFNC for palliative care with a individualized decision and with the agreement of the patient and their family, with clear communication of the treatment goals.

#### **Chronic Use of HFNC in Rehabilitation**

HFNC offers theoretical potential benefits in exercise training and pulmonary rehabilitation for patients with chronic respiratory diseases, primarily COPD and ILD. These benefits include reducing muscle load and maintaining a constant FiO<sub>2</sub> despite high oxygen demands during exercise.

#### *Clinical Evidence for Use of HFNC During Rehabilitation in COPD Patients*

In COPD patients, HFNC can alleviate hyperinflation, reduce the work of breathing, and decrease dyspnea and fatigue during exercise training. HFNC achieves these effects by reducing respiratory muscle load, lowering respiratory rate, and prolonging expiratory time.<sup>73</sup> Chao et al. conducted a single crossover trial showing that HFNC improved self-paced exercise performance, with a statistically significant increase of 27.3 m in the 6MWT compared to COT. However, this improvement was slightly below the threshold for clinical significance, with no differences observed in dyspnea, blood pressure, respiratory rate, or heart rate between the two groups.<sup>74</sup>

In a small study, Cirio et al. found that using HFNC during constant-load exercise testing in COPD patients improved exercise time and oxygen saturation, while reducing perceptions of dyspnea and muscle fatigue compared to the Venturi mask, suggesting HFNC may enhance training endurance even without supplemental oxygen.<sup>75</sup>

Vitacca et al. also observed a significant increase in 6MWT, although endurance time improvements were not statistically significant during pulmonary rehabilitation programs.<sup>76</sup> A recent meta-analysis found that HFNC had little to no effect on quality of life, exercise capacity, or breathlessness during pulmonary rehabilitation in COPD patients, though improvements were noted in non-domiciliary oxygen patients.<sup>77</sup>

#### *Clinical Evidence for Use of HFNC During Rehabilitation in ILD Patients*

In ILD patients, HFNC has shown potential to improve endurance time,<sup>46</sup> though with no effects on 6MWT and limited effects on dyspnea. Harada et al., in a randomized controlled trial comparing HFNC and the Venturi mask, found that the HFNC group had increased endurance time, higher peripheral oxygen saturation, and reduced leg fatigue compared to the Venturi mask group. However, dyspnea, maximum heart rate, and comfort at 80% peak work rate were unaffected by HFNC.<sup>48</sup> Badenes et al., in a single exercise test, also reported an increase in endurance time.<sup>46</sup> Yanagita et al. recently suggested that HFNC without supplemental oxygen can increase SpO<sub>2</sub> levels during exercise in mild ILD patients.<sup>49</sup> In patients with lung cancer, a single study reported that HFNC significantly reduced dyspnea and increased endurance time when used at 100% FiO<sub>2</sub>.<sup>69</sup>

#### *Recommendations for Use of HFNC During Rehabilitation*

- The group suggests the use of HFNC to improve performance in the 6MWT and reduce dyspnea in some COPD patients during rehabilitation, although its effect on endurance time is unclear, with minimal impact on other physiological parameters such as heart rate, respiratory rate, and blood pressure.
- The group doesn't recommends using HFNC during rehabilitation in ILD patients because the evidence is limited and inconsistent, suggesting that HFNC may increase endurance time, but its effects on dyspnea remain minimal across reviewed studies.

#### **Setting and Titration Parameters in Chronic HFNC**

Home use of HFNC may require a different approach than hospital use, as the goals can vary. Given its application across diverse conditions with varying pathophysiology, a personalized approach should be employed to titrate parameters effectively.

#### *Setting the Flow in HFNC*

In hospital settings, flow is titrated to match or exceed the patient's peak inspiratory flow. In chronic home-based care, several factors may influence the required flow.

- Most studies in patients with stable COPD have shown that even a minimum flow of 20 L/min can generate physiological benefits, such as a reduction in neuro-respiratory drive.<sup>21</sup>
- Higher flows (>50 L/min) may exacerbate air trapping in COPD, potentially leading to high near-alveolar pressures.<sup>18,19</sup>
- In stable settings, higher flows may be less well tolerated. Since the washout of dead space primarily occurs during exhalation, and stable patients typically have a lower respiratory rate, the benefits can be attained with lower flows than in acute care.
- Most studies in COPD have utilized flow rates between 20 and 30 L/min.<sup>25–27</sup>
- In bronchiectasis, flows are typically set between 20 and 40 L/min based on patient tolerance, with a mean tolerated flow of 33 L/min.<sup>24</sup>

- In acute care, high flows are necessary to maintain a constant inspired  $\text{FiO}_2$ . However, in home care, patients are more stable, with lower peak inspiratory flows and generally lower  $\text{FiO}_2$  requirements.<sup>78</sup>
- The goals for flow setting should include improvements in arterial blood gases and relief of dyspnea while ensuring patient tolerance.
- In most cases, flows between 20 and 30 L/min are sufficient and well tolerated.

#### Setting Temperature in HFNC

The standard goal is to maintain a temperature of 37 °C, though this may not be well tolerated in hotter climates. Many trials set temperature targets between 34 and 37 °C, aiming for optimal humidification at 37 °C. A practical approach is to start at 31 °C and gradually increase to 37 °C as tolerated.

#### Setting $\text{FiO}_2$ in HFNC

For home use, the management of severe hypoxemia is less of a focus compared to acute care, with supplemental oxygen requirements typically not exceeding 10–15 L/min. Conventional oxygen sources (static concentrators) are usually limited to supplying 8–9 L/min, while liquid oxygen can supply up to 15 L/min. Thus, delivered  $\text{FiO}_2$  is often below 50%. Most home care devices are not approved for more than 15 L/min of supplemental oxygen flow.

In COPD studies, supplemental oxygen flow rarely exceeded 2 L/min.<sup>8,25–27</sup> In bronchiectasis, many patients required no supplemental oxygen, with a mean  $\text{FiO}_2$  of 21%.<sup>24</sup> The recommendation is to adjust supplemental oxygen to maintain  $\text{SpO}_2$  within the desired range (usually 90–92%).

#### Setting Patient Interface in HFNC

The recommended approach is to use nasal cannulas that occlude approximately 50% of the nostrils. There is currently no real-life data to support the preference of asymmetrical nasal cannulas over conventional ones in home care settings.

#### Setting Compliance to HFNC Treatment

Studies suggest that a mean usage of 6–8 h per day is sufficient to achieve benefits, with some trials reporting usage exceeding 7 h per day.<sup>26</sup> It is recommended to use HFNC primarily during nocturnal hours and as long as tolerated unless combined with NIV.<sup>25</sup>

#### Recommendations for Setting and Titrating Parameters in Chronic HFNC

- The group recommends using HFNC with flows between 20 and 30 L/min for effective and well-tolerated treatment.
- The group recommends using HFNC starting with a temperature of 31 °C and progressively increase to 37 °C as tolerated.
- The group recommends using HFNC with a supplemental  $\text{O}_2$  flow adjusted to achieve the desired  $\text{SpO}_2$  range (usually 90–92%).
- The group recommends using HFNC at least during nocturnal hours.

#### HFNC Therapy Prescription in Spain

HFNC can be prescribed in various regions of Spain, although its implementation still lacks uniformity across the country.<sup>79</sup> To facilitate its widespread use, HFNC must be included in the technical specifications of tenders for home respiratory therapies or



Fig. 1. Regions with the possibility of prescribing HFNC in Spain.

offered as an improvement by the winning home care provider. This allows its inclusion even if it is not explicitly mentioned in the initial tender.

The fact that public tenders for home respiratory therapies, where HFNC is included, are drafted by regional health administrations<sup>80</sup> in collaboration with the scientific community—establishing the financing model, conditions, and quality criteria for the service—leads to significant heterogeneity in these aspects, resulting in disparities in services provided to patients across different regions.<sup>81</sup>

From 2018 to 2021, approximately half of the published tenders included the possibility of prescribing HFNC (e.g., Aragón through a special agreement, Ceuta, Galicia, Madrid, and Murcia),<sup>82–85</sup> while others excluded it (e.g., Catalonia, Cantabria, Jaén, Córdoba, Melilla, and the Balearic Islands).<sup>86–88</sup> Starting in 2022, there has been a noticeable shift, with nearly all tenders (e.g., Aragón, Almería, Extremadura, the Basque Country, and Cantabria)<sup>89–93</sup> incorporating HFNC. However, Málaga (published in 2022)<sup>94</sup> and Castilla y León<sup>95</sup> (pending completion) have not yet included it. Full implementation will depend on the progressive update of various tenders (Fig. 1).

#### Recommendations for HFNC Therapy Prescription in Spain

- It is recommended to review the technical specifications or the winning tender for the relevant region to gain a detailed understanding of the services provided and assess whether HFNC is included.

#### Limitations

The lack of meta-analyses and the heterogeneity of available studies, comprising a mix of randomized controlled trials and lower-quality observational studies, constrain the strength of evidence supporting the use of home high-flow nasal cannula (HFNC). Notably, there is a current shortage of multicenter studies in this field. Furthermore, no studies have conducted a cost-benefit analysis assessing the economic impact of home HFNC use. As this represents an emerging technology, it is crucial to demonstrate a clear balance between cost and clinical benefit. As we know, there is only a guideline published about this subject, the chronic HFNC Danish guideline.<sup>96</sup> It is reviewed too in a chapter of long-term oxy-

gen therapy Australia and New Zealand guideline.<sup>97</sup> Therefore, the aim of this document is to establish SEPAR's initial position on the use of these therapies, acknowledging that the development of a clinical practice guideline will require more robust future evidence.

## Conclusion

In conclusion, the chronic use of HFNC at home represents a novel treatment that could aid in managing patients with chronic respiratory diseases, particularly those with frequent exacerbations or poor secretion management. It may also be beneficial in the palliative care of respiratory patients. Additionally, the chronic use of HFNC could positively impact the exercise capacity of these patients. However, the current scientific evidence on this subject remains limited, and further studies are required to better elucidate the utility of this therapy. The results of two ongoing studies involving patients with COPD are expected soon.<sup>98,99</sup> Regarding the prescription of HFNC in Spain, significant heterogeneity has been observed across regions, underscoring a clear area for improvement.

## Appendix A. Supplementary Data

Supplementary data associated with this article can be found in the online version available at <https://doi.org/10.1016/j.arbres.2025.04.010>.

## References

- Luján M, Peñuelas Ó, Cinesi Gómez C, García-Salido A, Moreno Hernando J, Romero Berrocal A, et al. Summary of recommendations and Key Points of the Consensus of Spanish Scientific Societies (SEPAR, SEMICYUC, SEMES, SECIP, SENE, SEDAR, SENP) on the Use of Non-Invasive Ventilation and High-Flow Oxygen Therapy with Nasal Cannulas in Adult, Pediatric, and Neonatal Patients With Severe Acute Respiratory Failure. *Arch Bronconeumol* (Engl Ed). 2021;57(6):415–27. <http://dx.doi.org/10.1016/j.arbr.2021.04.003>.
- World Health Organization. The top 10 causes of death. [www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death](http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death) [accessed 16.4.21].
- Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. *Arch Bronconeumol*. 2023;59:232–48. <http://dx.doi.org/10.1016/j.arbres.2023.02.009>.
- Guan WJ, Han XR, de la Rosa-Carrillo D, Martínez-García MA. The significant global economic burden of bronchiectasis: a pending matter. *Eur Respir J*. 2019;53(2):1802392. <http://dx.doi.org/10.1183/13993003.02392.2018>.
- Martínez-García MA, Oscullo G, Gómez-Olivas JD, Oliveira C, Girón R, García-Clemente M, et al. Bronchiectasis: changes in the characterization of patients during 20 years of follow-up. Data from the Spanish Bronchiectasis Registries. *Arch Bronconeumol*. 2023;59:688–90. <http://dx.doi.org/10.1016/j.arbres.2023.07.023>.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–71. [http://dx.doi.org/10.1016/S0140-6736\(14\)61682-2](http://dx.doi.org/10.1016/S0140-6736(14)61682-2).
- Ergen B, Oczkowski S, Rochwerf B, Carlucci A, Chatwin M, Clini E, et al. European Respiratory Society Guideline on long-term home non-invasive ventilation for management of chronic obstructive pulmonary disease. *Eur Respir J*. 2019;54(3):1901003. [http://dx.doi.org/10.1016/S0140-6736\(14\)61682-2](http://dx.doi.org/10.1016/S0140-6736(14)61682-2).
- Vega Pittao ML, Schifano G, Pisani L, Nava S. Home high-flow therapy in patients with chronic respiratory diseases: physiological rationale and clinical results. *J Clin Med*. 2023;12:2663. <http://dx.doi.org/10.3390/jcm12072663>.
- Díaz Lobato S, Carratalá Perales JM, Montiel G, Alonso Iñigo JM. High-flow nasal cannula ventilatory modalities. *Arch Bronconeumol*. 2023. <http://dx.doi.org/10.1016/j.arbres.2023.09.016>. S0300-2896(23)00313-7. Epub ahead of print.
- Pitre T, Abbasi S, Su J, Mah J, Zeraatkar D. Home high flow nasal cannula for chronic hypercapnic respiratory failure in COPD: a systematic review and meta-analysis. *Respir Med*. 2023;219:107420. <http://dx.doi.org/10.1016/j.rmed.2023.107420>.
- Jácome C, Jácome M, Correia S, Flores I, Farinha P, Duarte M, et al. Effectiveness, adherence and safety of home high flow nasal cannula in chronic respiratory disease and respiratory insufficiency: a systematic review. *Arch Bronconeumol*. 2024;60(8):490–502. <http://dx.doi.org/10.1016/j.arbres.2024.05.001>.
- Huang X, Du Y, Ma Z, Zhang H, Jun L, Wang Z, et al. High-flow nasal cannula oxygen versus conventional oxygen for hypercapnic chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. *Clin Respir J*. 2021;15:437–44. <http://dx.doi.org/10.1111/crj.13317>.
- Luján M. Home high-flow oxygen therapy should be considered in patients with COPD and chronic respiratory failure. *Arch Bronconeumol*. 2023;59(1):5–6. <http://dx.doi.org/10.1016/j.arbres.2022.10.009>.
- Shrier I, Boivin J-F, Steele RJ, Platt RW, Furlan A, Kakuma R, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. *Am J Epidemiol*. 2007;166:1203–9. <http://dx.doi.org/10.1093/aje/kwm189>.
- Williams R, Rankin N, Smith T, Galler D, Seakins P. Relationship between the humidity and temperature of inspired gas and the function of the airway mucosa. *Crit Care Med*. 1996;24. <http://dx.doi.org/10.1097/00003246-199611000-00025>.
- Möller W, Celik G, Feng S, Bartenstein P, Meyer G, Eickelberg O, et al. Nasal high flow clears anatomical dead space in upper airway models. *J Appl Physiol*. 2015;118:1525–32. <http://dx.doi.org/10.1152/japplphysiol.00934.2014>.
- Pisani L, Fasano L, Corcione N, Comellini V, Musti MA, Brandao M, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. *Thorax*. 2017;72:373. <http://dx.doi.org/10.1136/thoraxjnl-2016-209673>.
- Naya Prieto A, López Chang C, Carballosa de Miguel MDP, Fernández Ormaechea MI, Zambrano Chacón MdLÁ, Jiménez Hiscock L, et al. High-flow oxygen: respiratory mechanics in lung alveoli of patients after acute respiratory failure. *Open Respir Arch*. 2024;6:100335. <http://dx.doi.org/10.1016/j.opresp.2024.100335>.
- Heili-Frades S, Naya Prieto A, Carballosa de Miguel P. New questions, warmings and answers related to high flow therapy in 2022. *Arch Bronconeumol*. 2023;59:409–11. <http://dx.doi.org/10.1016/j.arbres.2022.09.003>.
- Natalini D, Grieco DL, Santantonio MT, Mincione L, Toni F, Anzellotti GM, et al. Physiological effects of high-flow oxygen in tracheostomized patients. *Ann Intensive Care*. 2019;9:114. <http://dx.doi.org/10.1186/s13613-019-0591-y>.
- D'Cruz RF, Hart N, Katsakos G. High-flow therapy: physiological effects and clinical applications. *Breathe*. 2020;16:200224. <http://dx.doi.org/10.1183/20734735.0224-2020>.
- Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomized crossover trial. *Thorax*. 2016;71:759–61. <http://dx.doi.org/10.1136/thoraxjnl-2015-207962>.
- Mauri T, Turriani C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. *Am J Respir Crit Care Med*. 2017;195:1207–15. <http://dx.doi.org/10.2147/OAEM.S180197>.
- Crimi C, Nolasco S, Campisi R, Nigro M, Impellizzeri P, Cortegiani A, et al. Long-term domiciliary high-flow nasal therapy in patients with bronchiectasis: a preliminary retrospective observational case-control study. *J Clin Med*. 2022;11. <http://dx.doi.org/10.3390/jcm11247323>.
- Lopez-Campos JL, Caballero Eraso C. Home high-flow nasal cannula oxygen therapy for stable hypercapnic COPD: so far, so good. *Arch Bronconeumol*. 2023;59:71–2. <http://dx.doi.org/10.1016/j.arbres.2022.10.001>.
- Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. *Respir Med*. 2010;104(4):525–33. <http://dx.doi.org/10.3390/jcm11247323>.
- Nagata K, Horie T, Chohnabayashi N, Jinta T, Tsugitomi R, Shiraki A, et al. Home high-flow nasal cannula oxygen therapy for stable hypercapnic COPD: a randomized clinical trial. *Am J Respir Crit Care Med*. 2022;206(11):1326–35. <http://dx.doi.org/10.3390/jcm11247323>.
- Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1195–205. <http://dx.doi.org/10.3390/jcm11247323>.
- Weinreich UM. Domiciliary high-flow treatment in patients with COPD and chronic hypoxic failure: in whom can we reduce exacerbations and hospitalizations? *PLOS ONE*. 2019;14(12):e0227221. <http://dx.doi.org/10.1371/journal.pone.0227221>.
- Storgaard LH, Hockey HU, Weinreich UM. Development in PaCO<sub>2</sub> over 12 months in patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal cannula-post-hoc analysis from a randomized controlled trial. *BMJ Open Respir Res*. 2020;7(1):e000712. <http://dx.doi.org/10.1136/bmjresp-2020-000712>.
- Theunisse C, de Graaf NTC, Braam AWE, Vonk GC, Baart SJ, Ponssen HH, et al. The effects of home high-flow nasal cannula oxygen therapy on clinical outcomes in patients with severe COPD and frequent exacerbations. *J Clin Med*. 2025;14(3):868. <http://dx.doi.org/10.3390/jcm14030868>.
- Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, et al. Domiciliary high-flow nasal cannula oxygen therapy for patients with stable hypercapnic chronic obstructive pulmonary disease. A multicenter randomized crossover trial. *Ann Am Thorac Soc*. 2018;15(4):432–9. <http://dx.doi.org/10.1513/AnnalsATS.201706-425OC>.
- Bräunlich J, Dellweg D, Bastian A, Budweiser S, Randerath W, Triché D, et al. Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD. *Int J Chron Obstruct Pulmon Dis*. 2019;14:1411–21. <http://dx.doi.org/10.2147/COPD.S206111>.
- Solarat B, Perea L, Faner R, de La Rosa D, Martínez-García MÁ, Sibila O. Pathophysiology of chronic bronchial infection in bronchiectasis. *Arch Bronconeumol*. 2023;59:101–8. <http://dx.doi.org/10.1016/j.arbres.2022.09.004>.



35. Alcaraz-Serrano V, Sanz-Fraile H, Bueno-Freire L, Farré R, Otero J, Vázquez N, et al. Association between viscoelastic characteristics and sputum colour in patients with bronchiectasis. *Arch Bronconeumol*. 2023;59:406–8, <http://dx.doi.org/10.1016/j.arbres.2023.02.011>.
36. Maselli DJ, Diaz AA. Mortality risk in bronchiectasis. *Arch Bronconeumol*. 2024;60:333–5, <http://dx.doi.org/10.1016/j.arbres.2024.04.006>.
37. Simioli F, Fiorentino G, Cauteruccio R, Coppola A, Imitazione P, Marotta A, et al. Long-term high flow nasal cannula therapy in primary and secondary bronchiectasis. *Healthcare (Basel)*. 2023;11, <http://dx.doi.org/10.3390/healthcare11091250>.
38. Good WR, Garrett J, Hockey HUP, Jayaram L, Wong C, Rea H. The role of high-flow nasal therapy in bronchiectasis: a post hoc analysis. *ERJ Open Res*. 2021;7, <http://dx.doi.org/10.1183/23120541.00711-2020>.
39. Calabrese C, Nolasco S, Annunziata A, Sola A, Imitazione P, Campisi R, et al. Long-term high-flow nasal therapy in patients with bronchiectasis of different severity: a retrospective cohort study. *J Clin Med*. 2024;13(20):6146, <http://dx.doi.org/10.3390/jcm13206146>.
40. Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. *Value Health*. 2014;17:320–7, <http://dx.doi.org/10.1016/j.jval.2014.01.007>.
41. Cobo Sanchez L, Ruiz Herrero C, Cobos I, Bepin J, Gadea C, Cerdá-Cortés P, et al. Benefits of a homecare integral patient support program in idiopathic pulmonary fibrosis. *Arch Bronconeumol*. 2023;59:526–30, <http://dx.doi.org/10.1016/j.arbres.2023.03.008>.
42. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochweg B, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. *JAMA*. 2020;324(1):57–67, <http://dx.doi.org/10.1001/jama.2020.9524>.
43. Oczkowski S, Ergon B, Bos L, Chatwin M, Ferrer M, Gregoretti C, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. *Eur Respir J*. 2022;59(4):2101574, <http://dx.doi.org/10.1183/13993003.01574-2021>.
44. Pagliaro R, Aronne L, Fomez R, Ferri V, Montella A, Sanduzzi Zamparelli S, et al. High-flow nasal cannula system in respiratory failure associated with interstitial lung diseases: a systematic review and narrative synthesis. *J Clin Med*. 2024;13(10):2956, <http://dx.doi.org/10.3390/jcm13102956>.
45. Weinreich UM, Burchardt C, Huremovic J. The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – a pilot study. *Chron Respir Dis*. 2022;19, <http://dx.doi.org/10.1177/14799731221137085>, 14799731221137085.
46. Badenes-Bonet D, Cejudo P, Rodó-Pin A, Martín-Ontiyuelo C, Chalela R, Rodríguez-Portal JA, et al. Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial. *BMC Pulm Med*. 2021;21(1):355, <http://dx.doi.org/10.1186/s12890-021-01727-9>.
47. Al Chikhanie Y, Veale D, Verges S, Hérent F. The effect of heated humidified nasal high flow oxygen supply on exercise tolerance in patients with interstitial lung disease: a pilot study. *Respir Med*. 2021;186:106523, <http://dx.doi.org/10.1016/j.rmed.2021.106523>.
48. Harada J, Nagata K, Morimoto T, Iwata K, Matsunashi A, Sato Y, et al. Effect of high-flow nasal cannula oxygen therapy on exercise tolerance in patients with idiopathic pulmonary fibrosis: a randomized crossover trial. *Respirology*. 2022;27(2):144–51, <http://dx.doi.org/10.1111/resp.14176>.
49. Yanagita Y, Arizono S, Yokomura K, Ito K, Machiguchi H, Tawara Y, et al. Enhancing exercise tolerance in interstitial lung disease with high-flow nasal cannula oxygen therapy: a randomized crossover trial. *Respirology*. 2024;29(6):497–504, <http://dx.doi.org/10.1111/resp.14684>.
50. Chihara Y, Tsuboi T, Sumi K, Sato A. Effectiveness of high-flow nasal cannula on pulmonary rehabilitation in subjects with chronic respiratory failure. *Respir Investig*. 2022;60(5):658–66, <http://dx.doi.org/10.1016/j.resinv.2022.05.002>.
51. Dolidon S, Dupuis J, Molano Valencia LC, Salaün M, Thiberville L, et al. Characteristics and outcome of patients set up on high-flow oxygen therapy at home. *Ther Adv Respir Dis*. 2019;13, <http://dx.doi.org/10.1177/1753466619879794>, 1753466619879794.
52. Grünewaldt A, Rohde G. Nasal high-flow oxygen therapy in chronic respiratory failure for homecare applications – a feasibility study. *J Clin Med*. 2024;13(15):4525, <http://dx.doi.org/10.3390/jcm13154525>.
53. Duarte JC, Santos O, Lousada C, Reis-Pina P. High-flow oxygen therapy in palliative care: a reality in a near future? *Pulmonology*. 2021;27(6):479–80, <http://dx.doi.org/10.1016/j.pulmoe.2021.08.003>.
54. Huang JY, Steele P, Dabscheck E, Smallwood N. Nasal high flow therapy for symptom management in people receiving palliative care. *J Pain Symptom Manage*. 2022;63(2):e237–45, <http://dx.doi.org/10.1016/j.jpainsymman.2021.09.016>.
55. Storgaard LH, Weinreich UM, Laursen BS. COPD patients' experience of long-term domestic oxygen-enriched nasal high flow treatment: a qualitative study. *COPD*. 2020;17(2):175–83, <http://dx.doi.org/10.1080/15412555.2020.1736998>.
56. Spicuzza L, Schisano M. High-flow nasal cannula oxygen therapy as an emerging option for respiratory failure: the present and the future. *Ther Adv Chronic Dis*. 2020;11, <http://dx.doi.org/10.1177/2040622320920106>, 2040622320920106.
57. Lemyze M, Dupré C. Oxygénothérapie nasale à haut débit: soins palliatifs et aspects éthiques [High flow oxygen via nasal cannula: Palliative care and ethical considerations]. *Rev Mal Respir*. 2022;39(4):367–75, <http://dx.doi.org/10.1016/j.rmr.2022.02.061>. French.
58. Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. *Respir Care*. 2016;61(4):529–41, <http://dx.doi.org/10.4187/respcare.04577>.
59. Mauri T, Wang YM, Dalla Corte F, Corcione N, Spinelli E, Pesenti A. Nasal high flow: physiology, efficacy and safety in the acute care setting, a narrative review. *Open Access Emerg Med*. 2019;11:109–20, <http://dx.doi.org/10.2147/OAEM.S180197>.
60. Carratalá JM, Diaz-Lobato S, Brouzet B, Más-Serrano P, Rocamora JLS, Castro AG, et al. Efficacy and safety of high-flow nasal cannula therapy in elderly patients with acute respiratory failure. *Pulmonology*. 2024;30(5):437–44, <http://dx.doi.org/10.1016/j.pulmoe.2023.01.004>.
61. Bode S, Grove G. Use of humidified high flow nasal oxygen in community palliative care: a case report. *Palliat Med Rep*. 2020;1(1):179–82, <http://dx.doi.org/10.1089/pmr.2020.0026>.
62. Shah N, Mehta Z, Mehta Y. High-flow nasal cannula oxygen therapy in palliative care #330. *J Palliat Med*. 2017;20(6):679–80, <http://dx.doi.org/10.1089/jpm.2017.0108>.
63. Peters SG, Holets SR, Gay PC. High-flow nasal cannula therapy in do-not-intubate patients with hypoxemic respiratory distress. *Respir Care*. 2013;58(4):597–600, <http://dx.doi.org/10.4187/respcare.01887>.
64. Shibata H, Takeda N, Suzuki Y, Katoh T, Yoshida N, Hasegawa Y, et al. Editors' Choice: Effects of high-flow nasal cannula oxygen therapy on oral intake of do-not-intubate patients with respiratory diseases. *Nagoya J Med Sci*. 2021;83(3):509–22, <http://dx.doi.org/10.18999/nagjms.83.3.509>.
65. Xu Z, Li P, Zhang C, Ma D. Effect of heated humidified high-flow nasal cannula (HFNC) oxygen therapy in dyspnea patients with advanced cancer, a randomized controlled clinical trial. *Support Care Cancer*. 2022;30(11):9093–100, <http://dx.doi.org/10.1007/s00520-022-07330-w>.
66. Ruangsomboon O, Dorongthom T, Chakorn T, Monsomboon A, Praphruetkit N, Limsuwat C, et al. High-flow nasal cannula versus conventional oxygen therapy in relieving dyspnea in emergency palliative patients with do-not-intubate status: a randomized crossover study. *Ann Emerg Med*. 2020;75(5):615–26, <http://dx.doi.org/10.1016/j.annemergmed.2019.09.009>.
67. Luján M, Cinesi Gómez C, Peñuelas O, Ferrando C, Heili-Frades SB, Carratalá Perales JM, et al. Multidisciplinary consensus on the management of non-invasive respiratory support in the COVID-19 patient. *Arch Bronconeumol*. 2024;60:285–95, <http://dx.doi.org/10.1016/j.arbres.2024.02.017>.
68. Koyauchi T, Hasegawa H, Kanata K, Kakutani T, Amano Y, Ozawa Y, et al. Efficacy and tolerability of high-flow nasal cannula oxygen therapy for hypoxemic respiratory failure in patients with interstitial lung disease with do-not-intubate orders: a retrospective single-center study. *Respiration*. 2018;96(4):323–9, <http://dx.doi.org/10.1159/000489890>.
69. Vianello A, Arcaro G, Molena B, Turato C, Braccioni F, Paladini L, et al. High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis. *Ther Adv Respir Dis*. 2019;13, <http://dx.doi.org/10.1177/1753466619847130>, 1753466619847130.
70. Hui D, Mahler DA, Larsson L, Wu J, Thomas S, Harrison CA, et al. High-flow nasal cannula therapy for exertional dyspnea in patients with cancer: a pilot randomized clinical trial. *Oncologist*. 2021;26(8):e1470–9, <http://dx.doi.org/10.1002/onco.13624>.
71. Epstein AS, Hartridge-Lambert SK, Ramaker JS, Voigt LP, Portlock CS. Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center. *J Palliat Med*. 2011;14(7):835–9, <http://dx.doi.org/10.1089/jpm.2011.0005>.
72. Mercadante S, Giuliana F. High flow nasal therapy in the management of hypoxemic dyspnea at the end of life. *Support Care Cancer*. 2021;29(11):6179–81, <http://dx.doi.org/10.1007/s00520-021-06279-6>.
73. Boccatonda A, Groff P. High-flow nasal cannula oxygenation utilization in respiratory failure. *Eur J Intern Med*. 2019;64:10–4, <http://dx.doi.org/10.1016/j.ejim.2019.04.010>.
74. Chao KY, Liu WL, Nassef Y, Tseng CW, Wang JS. Effects of high-flow nasal cannula with oxygen on self-paced exercise performance in COPD: a randomized cross-over trial. *Medicine (Baltimore)*. 2021;100(51):e28032, <http://dx.doi.org/10.1097/MD.00000000000028032>.
75. Cirio S, Piran M, Vitacca M, Piaggi G, Ceriana P, Prazzoli M, et al. Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation. *Respir Med*. 2016;118:128–32, <http://dx.doi.org/10.1016/j.rmed.2016.08.004>.
76. Vitacca M, Paneroni M, Zampogna E, Visca D, Carlucci A, Cirio S, et al. High-flow oxygen therapy during exercise training in patients with chronic obstructive pulmonary disease and chronic hypoxemia: a multicenter randomized controlled trial. *Phys Ther*. 2020;100(8):1249–59, <http://dx.doi.org/10.1093/ptj/pzaa076>.
77. Oltra G, Ricciardelli M, Virgilio S, Fernandez Parmo D, Ruiz A, Liquitay CME, et al. High-flow nasal cannula during pulmonary rehabilitation for people with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Physiother Res Int*. 2024;29(2):e2088, <http://dx.doi.org/10.1002/pri.2088>.
78. Li J, Albuaïnain FA, Tan W, Scott JB, Roca O, Mauri T. The effects of flow settings during high-flow nasal cannula support for adult subjects: a systematic review. *Crit Care*. 2023;27(1):78, <http://dx.doi.org/10.1186/s13054-023-04361-5>.
79. Moreno-Zabaleta R, García Torres P, Sayas J, Luján M. High-flow nasal therapy trends in Spain: a survey-based perspective. *Open Respir Arch*. 2024;6(1):100303, <http://dx.doi.org/10.1016/j.opresp.2024.100303>.
80. Ley General de Sanidad (Ley 14/1986 de 25 de Abril) (BOE 102 del 25-4-1986). Ministerio de Sanidad y Consumo. Madrid, 1986.
81. EY 2021. Terapias Respiratorias personalizadas: Calidad asistencial, eficiencia y resultados en salud. Available from: <https://fenin.es/informet-terapias-respiratorias-domiciliarias-personalizadas-calidad-asistencial-eficiencia-y-resultados-en-salud/>



82. Servicio de oxigenoterapia medicinal y otras terapias respiratorias domiciliarias para pacientes del INGESA en Ceuta. Available from: <https://contrataciondelestado.es/wps/portal/!ut/p/b0/DcqxCoAgEADQr2k-Ww0HhppCCgrzljhS4vCOBvP7a3zwAGEHzFT5osJ3jvntfAiPcl6dD4VEwIF8cqHzD2ABAdkPvcBFNbevmey4meryGhejGoW91vCk1H9y5stb/>.
83. Contratación de servicios de terapia respiratoria a domicilio nas Xerencias de Xestión Integrada de Santiago de Compostela, Vigo e Pontevedra-Salnés do Servizo Galego de Saúde. Available from: <https://www.contratosdeg Galicia.gal/licitacion?N=540136>.
84. Prestación de terapias respiratorias domiciliaria y otras técnicas de ventilación asistida en el ámbito de la Comunidad de Madrid, de ref. «CA 3/2018 Terapias Respiratorias domiciliarias» a adjudicar por procedimiento abierto con pluralidad de criterios. Available from: <https://contratos-publicos.comunidad.madrid/contrato-publico/prestacion-terapias-respiratorias-domiciliaria-otras-tecnicas-ventilacion-asistida>.
85. Prestación del servicio de terapias respiratorias domiciliarias y otras técnicas de ventilación asistida para los pacientes que residen en el ámbito de la áreas de salud i, iii, iv, v, vi, vii, ix de la comunidad autónoma de la región de murcia. Available from: [https://www.carm.es/web/pagina?IDCONTENIDO=1617&IDTIPO=200&RASTRO=c709\\$m&exp=8a2629247052236301705361614116c4](https://www.carm.es/web/pagina?IDCONTENIDO=1617&IDTIPO=200&RASTRO=c709$m&exp=8a2629247052236301705361614116c4).
86. Contractació Teràpia respiratòria domiciliària (exp: OX/08 i OX/12) (fins a finalització dels contractes, més els contractes d'emergència relacionats). Available from: <https://catsalut.gencat.cat/ca/coneixatsalut/transparencia/contractes-convenis-subvencions/relacio-contractes/serveis-sanitaris/atencioextrahospitalaria/terapias-respiratorias/contractacio-mitjancant-acord-marc-terapia-respiratoria-domicili-exp-trd-18>.
87. Servicio de oxigenoterapia medicinal y otras terapias respiratorias domiciliarias a pacientes del INGESA en Melilla. Available from: [https://contrataciondelestado.es/wps/wcm/connect/28d683bb-1ebc-40df-9b26-06ef20b70c0e/DOC\\_CD2021-845396.html?MOD=AJPERES](https://contrataciondelestado.es/wps/wcm/connect/28d683bb-1ebc-40df-9b26-06ef20b70c0e/DOC_CD2021-845396.html?MOD=AJPERES).
88. Servicio de terapias respiratorias domiciliarias en el ámbito de los Centros Sanitarios de la Plataforma Logística Sanitaria de Córdoba. Available from: [https://www.juntadeandalucia.es/haciendayadministracionpublica/apl/pdc\\_sirec/perfiles-licitaciones/detalle-licitacion.jsf?idExpediente=000000365933](https://www.juntadeandalucia.es/haciendayadministracionpublica/apl/pdc_sirec/perfiles-licitaciones/detalle-licitacion.jsf?idExpediente=000000365933).
89. Servicio de oxigenoterapia a domicilio y otras técnicas de ventilación nasal en la Comunidad Autónoma de Aragón. Available from: <https://contrataciondelestado.es/wps/portal/!ut/p/b0/04.Sj9CPykssy0xPLMnMz0vMAfjU1JTC3ly87KtUjLEnNyUuNzMpMzSxKTgQr0w.Wj9KMyU1zLcvQjy11LMpJM0vxCyvPygvNDIoyrVA3Myx1tbfULcnMdAbnUza4/>.
90. Servicio de terapias respiratorias domiciliarias en el ámbito de centros sanitarios integrados en la central provincial de compras de almería. Available: Junta de Andalucía – Temas: Detalle de licitación.(juntadeandalucia.es).
91. Acuerdo Marco con una única empresa para el servicio de terapias respiratorias domiciliarias (TRD) en el ámbito del Servicio Extremeño de Salud. 2022. Available from: [https://contrataciondelestado.es/wps/wcm/connect/1ac9be5a-6798-4042-8e4b-4417472c5f5c/DOC\\_CD2022-162103.html?MOD=AJPERES](https://contrataciondelestado.es/wps/wcm/connect/1ac9be5a-6798-4042-8e4b-4417472c5f5c/DOC_CD2022-162103.html?MOD=AJPERES).
92. Terapias respiratorias y otras técnicas de ventilación asistida para personas usuarias del Sistema Sanitario de Euskadi. Available from: <https://www.euskadi.eus/anuncio.contratacion/terapias-respiratorias-y-otras-tecnicas-ventilacion-asistida-personas-usuarias-del-sistema-sanitario-euskadi/web01-tramite/es/>.
93. Servicio de atención sanitaria respiratoria domiciliaria personalizada para usuarios del Servicio Cántabro de Salud en el ámbito de la Comunidad Autónoma de Cantabria. Available from: <https://contrataciondelestado.es/wps/portal/!ut/p/b0/DcrBCoAgDADQT9otKOiQUJ2DoOYIRloMpwmpUF9fxwcpNKyGAXU-KfEVSH6jsTYKB9cYm0jEbsl7J9r.AAto0Gz6loBuULK6Aubbz4-ML3o11FPbQvS-wABea6L/>.
94. Servicio de terapias respiratorias domiciliarias a los pacientes beneficiarios del servicio andaluz de salud en el ámbito de la competencia asistencial de los centros sanitarios adscritos al Servicio Andaluz de Salud de la provincia de Málaga (central provincial de compras de Málaga) (0000775/2022) (CCA +6.+D8-YH5) Available from: [https://www.juntadeandalucia.es/haciendayadministracionpublica/apl/pdc\\_sirec/perfiles-licitaciones/detalle-licitacion.jsf?idExpediente=539230](https://www.juntadeandalucia.es/haciendayadministracionpublica/apl/pdc_sirec/perfiles-licitaciones/detalle-licitacion.jsf?idExpediente=539230).
95. Servicio de Terapias Respiratorias Domiciliarias para los pacientes que residen en la Comunidad Autónoma de Castilla y León, a los que la Gerencia Regional de Salud tenga el deber de prestar asistencia sanitaria, previa prescripción autorizada. Available from: <https://www.contrataciondelestado.es/wps/portal/!ut/p/b0/04.Sj9CPykssy0xPLMnMz0vMAfjU1JTC3ly87KtUjLEnNyUuNzMpMzSxKTgQr0w.Wj9KMyU1zLcvQjyRwNiszCC0PCsvzMDULLXCsjvYLDy21t9Qtycx0BdVY3Vw!!/>.
96. Weinreich UM, Juhl KS, Søby Christophersen M, Gundestrup S, Hanifa MA, Jensen K, et al. The Danish respiratory society guideline for long-term high flow nasal cannula treatment, with or without supplementary oxygen. Eur Clin Respir J. 2023;10(1):2178600. <http://dx.doi.org/10.1080/20018525.2023.2178600>.
97. McDonald CF, Serginson J, AlShareef S, Buchan C, Davies H, Miller BR, et al. Thoracic Society of Australia and New Zealand clinical practice guideline on adult home oxygen therapy. Respirology. 2024;29(9):765–84. <http://dx.doi.org/10.1111/resp.14793>.
98. EPiC-HFT trial. Available from: <https://www.kcl.ac.uk/research/epic-hft>.
99. Home High Flow Oxygen to Reduce Acute Exacerbation of COPD (HIFAE). Available from: <https://ctv.veeva.com/study/home-high-flow-oxygen-to-reduce-acuteexacerbation-of-copd>.